382150 — OncoCross Co Balance Sheet
0.000.00%
- KR₩144bn
- KR₩123bn
- KR₩1bn
Annual balance sheet for OncoCross Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Cash and Equivalents | |||
| Short Term Investments | |||
| Cash and Short Term Investments | 7,008 | 16,642 | 20,751 |
| Net Total Accounts Receivable | |||
| Net Total Receivables | 36.1 | 46.8 | 300 |
| Prepaid Expenses | |||
| Total Current Assets | 7,196 | 16,763 | 21,101 |
| Gross Property, Plant And Equipment | |||
| Accumulated Depreciation | |||
| Net Property, Plant And Equipment | 976 | 566 | 1,012 |
| Net Intangible Assets | |||
| Other Long Term Assets | |||
| Total Assets | 8,400 | 17,586 | 22,548 |
| Accrued Expenses | |||
| Notes Payable / Short Term Debt | |||
| Current Portion of Long Term Debt / Capital Leases | |||
| Total Other Current Liabilities | |||
| Total Current Liabilities | 3,589 | 1,099 | 1,848 |
| Capital Lease Obligations | |||
| Total Long Term Debt | |||
| Total Debt | |||
| Total Liabilities | 3,705 | 1,099 | 2,091 |
| Common Stock | |||
| Additional Paid In Capital | |||
| Retained Earnings (Accumulated Deficit) | |||
| ESOP Debt Guarantee | |||
| Other Equity | |||
| Total Equity | 4,695 | 16,487 | 20,457 |
| Total Liabilities & Shareholders' Equity | 8,400 | 17,586 | 22,548 |
| Total Common Shares Outstanding |